ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

More Pharma Arts Reporting, Please

July 20, 2015 | APPEARED IN VOLUME 93, ISSUE 29

I read “Schooled in the Pharma Arts” with interest (C&EN, May 25, page 12). However, only Waisman Biomanufacturing is highlighted as a contract manufacturing organization making gene therapy drugs.

I am surprised by how many medical centers and universities have cooperated to create small Good Manufacturing Practices (GMP) production areas to make viral-based gene therapy drugs within hospitals. These facilities are establishing new methods to make and deliver genes to clinical trials with a small number of patients. Have you previously reported on this group of GMP facilities?

Bob Steininger
Cambridge, Mass.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment